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Kaposi sarcoma (KS) remains a highly incident and morbid cancer across sub-Saharan Africa (SSA).1 KS 
diagnosis requires multidisciplinary coordination between dermatology, oncology, and HIV departments, which 
makes patients vulnerable to care coordination gaps.2 Although KS diagnosis ideally requires skin biopsy followed 
by prompt pathologic confirmation, in resource-limited settings KS is often diagnosed clinically or subject to delays 
in pathologic diagnosis.2, 3 To better understand the role of dermatology in KS diagnosis and multidisciplinary care 
coordination, we conducted chart reviews and site assessments to evaluate the care cascade of KS patients at 
three HIV primary care networks in Southern, Eastern, and Western Africa. 
We evaluated the medical records of all adults ≥18 newly diagnosed with HIV-associated KS in Princess 
Marina Hospital (PMH) Botswana (2015-2017), Academic Model Providing Access to Healthcare (AMPATH) 
Kenya (2009-2012), and National Hospital Abuja (NHA) / University of Abuja Teaching Hospital (UATH) Nigeria 
(2009-2012). Across sites, KS severity at diagnosis was derived from the signs/symptoms recorded within 30 
days of diagnosis using AIDS Clinical Trials Group (ACTG) criteria.4 Authors performed site assessments for 
Botswana (VW, TR, SG), Kenya (DS, DM, NB, EF) and Nigeria (KI, VK, EJ), delineating biopsy types and referral 
patterns for patients with suspected KS. 
There were 604 KS cases diagnosed at AMPATH Kenya between 2009-2012, 192 at PMH Botswana 
between 2015-2017, and 34 at NHA/UATH Nigeria between 2009-2012 (Supplemental Table 1). The majority 
presented with advanced T1 disease (59.1% in Kenya, 77.6% in Botswana, 55.9% in Nigeria). Patient referrals 
and biopsy modality differed across sites (Table 1). In Botswana 100% of patients with suspected KS had a punch 
biopsy performed by a dermatologist. In contrast, in Kenya 45.3% of patients had a punch biopsy by a 
dermatologist or oncologist, while in Nigeria 29.4% of patients had an excisional biopsy by a surgeon or 
dermatologist (Figure 1).  
Partnerships between international sites and the hospitals in Botswana and Kenya facilitated free punch 
biopsy supplies. The Nigerian hospital represents the more typical biopsy model in SSA, where excisional biopsy 
is performed by a general surgeon or dermatologist.2 Excisional biopsy may be warranted in certain cases; 
however, it is more expensive to the patient and the healthcare system, may delay diagnosis, and increases 
procedural risk.2  
As a medically complex disease, HIV-associated KS requires care coordination between at least three 
departments: HIV, oncology, and dermatology. We identified facilitators such as punch biopsy usage, care 
coordination across departments, use of a single hospital identification number, international partnerships, and 
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task-shifting to make pathological KS diagnosis more accessible. Study limitations include reliance on 
retrospective data and inability to define reasons for diagnostic delays leading to advanced disease. 
We describe three unique models integrating dermatologic care into HIV-associated KS diagnosis across 
Southern, Eastern, and Western Africa. With the majority of our KS patients being diagnosed with advanced KS, 
investments in improved access to dermatologic care at both the community and tertiary care level, inexpensive 
and rapid biopsy services, and investment into histopathology are needed to address these disparities.  
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Table 1: Kaposi sarcoma care coordination by site. 
Princess Marina 
Hospital, Botswana 




20.3% 4.7% 1.5% 
Number of people living 
with HIV country-
wide**5 
350,000 1,400,000 1,800,000 
Biopsy Provider Dermatology Trained oncology 
nurses, dermatology 
Surgery, dermatology 
Type of Biopsies Punch biopsies Punch biopsies Excisional biopsies 
(Wedge biopsies). 
Rarely punch biopsies. 
Percentage of KS 
cases biopsy proven 
100% 45% 29% 
Percentage of KS 
cases referred to 
oncology 
100% 72% 32% 






Chemotherapy delivery Oncology department 
via four departments 
around the country 
Oncology department 
at tertiary (Moi 
Teaching and Referral 




UATH: HIV physicians 







HIV referrals as 
needed, single hospital 
medical record used 
across all clinics 
Referral basis; HIV and 
oncology patient 
medical records are 
separate and unlinked 
Referral basis and 
consults; single medical 





clinic; patients can be 
referred for on the spot 
HIV testing from all 
dermatology clinics 
Weekly HIV-
dermatology clinic Patients with suspected 
KS seen in 
dermatology clinic are 





biopsies, starts staging 
work up and transfers 
care to oncology which 
continues work-up, 
treatment and long 
term follow-up 
Oncology performs 
biopsies on suspected 
KS cases; if negative, 
refer to dermatology for 
clinical management 
NHA: patients with KS 
referred to oncology 
which provides 
chemotherapy and long 
term follow-up   
*All people ages 15-49 in 2018
**All people ages 15 and over in 2018
†Paclitaxel is preferential first line in Botswana, however is often unavailable 
Figure 1: Process maps of pathway to KS Diagnosis for patients with suspicious skin lesions presenting at PMH
Botswana, AMPATH Kenya and NHA/UATH Nigeria.
